GxVISION® Hereditary Cancer Risk Assessment
Hereditary cancers constitute 5-10% of all cancer cases. Genetic testing plays a crucial role in diagnosing these conditions, identifying at-risk patients, and ultimately improving outcomes.
Genetic Testing and Hereditary Cancers
Many of the genetic mutations responsible for known hereditary cancer syndromes have been identified. Genetic testing is instrumental in confirming whether a condition is inherited, pinpointing the specific genetic variations responsible, assessing cancer risk for related family members, and enhancing patient outcomes.
Otogenetics’ Comprehensive Panel specifically addresses genes implicated in multiple types of hereditary cancers. Leveraging Next Generation Sequencing technology, our advanced genetic testing platform ensures comprehensive coverage and accurate detection of genetic variations associated with cancer and cancer risk.
Next Generation Cancer Gene Panels Versus Gene by Gene Testing Society of Gynecologic Oncology (SGO) Clinical Practice Statement
“Advantages of cancer gene panels include decreased cost and improved efficiency of cancer genetic testing by decreasing the time involved, number of patient visits, and number of tests sent. A negative genetic test is more reassuring at eliminating the likelihood of inherited risk when all known genes for that phenotype have been assayed.”
- “Approximately 15% of all ovarian cancers are attributable to a BRCA1 or BRCA2 mutation.
- An additional 5-6% of ovarian cancers have gene mutations in other genes including the Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2), and BRIP1, RAD51D, RAD51C, PALB2, BARD1, and TP53”.
Indeed, data from 40,000+ hereditary cancer gene tests at Otogenetics show that additional genes contribute to more than 80% of the positive cases, while supporting the contribution from BRCA1 and BRCA2. Multi-gene testing allows for the identification of 40 to 50 percent more individuals with hereditary cancer gene mutations than is possible testing for BRCA1 and BRCA2 alone. The simultaneous evaluation of multiple genes is a highly cost-effective and time-effective option. In addition, some medical insurance allows coverage of genetic testing for a particular condition only once in a lifetime.
Otogenetics GxVISION® Hereditary Cancer Risk Assessment Tests
Linked to Breast, Ovarian, Endometrial, Colorectal, Lynch Syndrome, Gastric, Melanoma, Pancreatic, Polyposis, Prostate, Renal, Thyroid/Parathyroid, Uterine and other major cancers.
Otogenetics Test Advantages
- Technologically robust and clinically actionable testing by the most advanced NGS technology
- Quality detection of rare and common variants by high depth and complete sequence coverage
- Reliable reporting based on comprehensive external clinical genetic databases and an internal >100,000 patient database
- Experience among the first NGS laboratories for clinical testing and R&D
Mutations in each gene may be rare when evaluated individually, however they collectively account for a significant amount of hereditary cancer susceptibility.
This testing may be appropriate in a number of scenarios, particularly if the family history shares features of several different hereditary cancer syndromes with multiple cancer types.
Testing does not tell you if you currently have cancer.
Your test results tell you about your inherited risk of having breast and ovarian cancer, or other cancers.
A negative test result means that you do not have a gene mutation in what were evaluated in the Gene Panel Testing.
Although the gene test can detect the majority of mutations:
- You could have a gene mutation or type of mutations that the test wasn’t targeted to detect.
- Or if your family carries a high-risk gene mutation that researchers haven’t yet identified then the test would not be able to detect this gene mutation and you could be a carrier.
A negative test result does not eliminate the chance of developing non-hereditary cancer. You may have the same cancer risk as that of the general population.
A positive test result:
- means that you have a gene mutation that is associated with cancer.
- does not mean that you have cancer or that you will certainly have cancer.
- tells you that you have a higher risk of developing cancer compared with someone who does not have the mutation.
Education Center
Stay informed with our patient resources. Visit our Education Center to learn more.
FAQ's Billing & Insurance FAQs
Every patient should have access to highly accurate and affordable genetic testing. Otogenetics is committed to work with each patient to reach payment solutions. These may include:
- Working with your insurance provider to verify coverage.
- Flexible payment options billed over several months.
- Financial assistance for patients who qualify.
We encourage patients to call us for all billing questions, and to discuss payment solutions.
Please call us toll free at 1-855-686-4363, option 1.
Otogenetics is committed to working with patients to ensure that everyone has access to testing without financial burden.
- Medicaid patients will NOT have patient out of pocket responsibility.
- We treat all out-of-network claims as if they are in-network.
- We will work with all insurers (primary and secondary policies) to maximize your qualified coverage.
Otogenetics testing service is covered by many insurance plans, the exact amount you owe may vary based on your individual plan and financial situation.
Here is our commitment to you regarding costs:
- We will reach out to you if we estimate your cost could be more than $50 (the average out of pocket Otogenetics patients pay).
- We will discuss the estimate with you, and review your affordability.
You may receive information from your insurer, known as an Explanation of Benefits (EOB), regarding the test you received from Otogenetics.
An EOB from your insurer is NOT A BILL.
A bill for the test(s) provided by Otogenetics comes ONLY from Otogenetics.
If there is any patient out of pocket cost after Otogenetics has exhausted all options for reimbursement coverage and financial assistance, Otogenetics will reach out to you, the patient.
Next Steps
To get started, talk to your healthcare provider about requesting a carrier screen.
Your healthcare provider will take a blood or buccal draw and send it to our lab.
Otogenetics will analyze your DNA sample using our state-of-the-art technologies.
Once your screen is complete, your healthcare provider or a genetic counselor from Otogenetics may contact you to explain your results and answer any questions you have.